U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Substitute for form 1449/PTO				Complete if Known			
Cuboutu				Application Number	10/829,042		
INF	ORMATION	DIS	CLOSURE	Filing Date	April 21, 2004		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Trevor Barrowcliffe 1652		
				Art Unit			
				Examiner Name	Hope A. Robinson		
Sheet	1	of	1	Attorney Docket Number	674583-2001		

	NON PATENT LITERATURE DOCUMENTS					
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	ABSTRACT: M. Shima, et al., The Current Situation And Vision Of Plasma Protein Formulation, Biomedical Perspectives (1999) Vol. 8, No. 1, p. 99-107	✓				
	ABSTRACT: A. Yoshioka, Recombinant Factor VIII, 8. Recombinant Factor Formuation, Jap. J. Transfus. Med. (1992) Vol. 38, No. 6, p. 845-849					
	ABSTRACT: M. Arai, The Current Situation And Vision Of Plasma Protein; Biomed. Perspect. (1999) Vol. 9, No. 1, p. 108-117					
	Cite No.1	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ABSTRACT: M. Shima, et al., The Current Situation And Vision Of Plasma Protein Formulation, Biomedical Perspectives (1999) Vol. 8, No. 1, p. 99-107 ABSTRACT: A. Yoshioka, Recombinant Factor VIII, 8. Recombinant Factor VIII Formuation, Jap. J. Transfus. Med. (1992) Vol. 38, No. 6, p. 845-849 ABSTRACT: M. Arai, The Current Situation And Vision Of Plasma Protein;				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions greatly this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.